The MS Patient Community Panel – which will run alongside Ipsos’ MS Therapy Monitor – comprises 260 MS patients across the EU5 and US with a mix of treatment experiences. They will take part in a range of tasks throughout the year (both syndicated and proprietary), all moderated by Ipsos Healthcare’s MS experts. This format will enable subscribers to explore key topics throughout the year, whilst also tapping into the community to answer business questions as they arise.
Commented Paul O’Meara, Head of Real World Evidence in Autoimmune Diseases at Ipsos Healthcare:
As patients move from recipients to participants, there is an imperative for pharma to put patients at the heart of current and future business models. Designed with this objective in mind, the MS Community will enable our clients to identify unmet patient needs, optimise their patient communications, assess new ideas, and develop personalised medicine strategies for those living with MS.
As just one example of the insights generated, the Community’s most recent syndicated self-monitoring task revealed that 88% of MS patients currently self-monitor an aspect of their own health or lifestyle – perceiving themselves to be their own health advocates. This self-determined responsibility reflects limited neurologist input, with just 20% of patients stating their healthcare provider has ever mentioned the concept of self-monitoring to them.